Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma

Autor:	Attilio Olivieri, Massimo Offidani, Giorgia Mancini, Antonella Poloni, Debora Capelli, Guido Gini, GianMario Raggetti, Pietro Leoni, Martina Chiarucci, Elena Inglese, Mauro Montanari, Monica Calandrelli, Stefania Mancini, Ilaria Scortechini
Rok vydání:	2013
Předmět:	Melphalan Oncology Cancer Research medicine.medical_specialty Transplantation Conditioning Lymphoma medicine.medical_treatment Hematopoietic stem cell transplantation Transplantation Autologous Amifostine immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Outpatients medicine Humans neoplasms Etoposide business.industry Cytarabine Hematopoietic Stem Cell Transplantation Hematology medicine.disease Carmustine Transplantation Treatment Outcome surgical procedures operative business medicine.drug
Zdroj:	Leukemia & Lymphoma. 55:1657-1660
ISSN:	1029-2403 1042-8194
Popis:	BEAM (BCNU, etoposide, cytarabine, melphalan) is standard conditioning for autologous stem cell transplant (ASCT) in Hodgkin disease (HD) and in non-Hodgkin lymphoma (NHL) [1]. Growth factors (GFs)...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3976c10dfc3142200123aee0f962e9d https://doi.org/10.3109/10428194.2013.842989 Zobrazit plný text záznamu